Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
Q1 2024 vs. Q4 2023
How the institutions holding Damora Therapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 22 | 26 | +4 |
| Shares | 3.85M | 3.96M | +105.8K (+2.7%) |
| Value | $2.77M | $3.09M | +$314.5K (+11.3%) |
New holders (7)
Institutions that held Damora Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 26,213 | $20.4K | 0.00% |
| Summit Trail Advisors, LLC | 25,000 | $19.5K | 0.00% |
| XTX Topco Ltd | 18,247 | $14.2K | 0.00% |
| Millennium Management LLC | 14,002 | $10.9K | 0.00% |
| ICA Group Wealth Management, LLC | 750 | $585 | 0.00% |
| Northwestern Mutual Wealth Management Co | 500 | $390 | 0.00% |
| Harbour Investments, Inc. | 200 | $156 | 0.00% |
Sold out (3)
Institutions that held Damora Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Two Sigma Securities, LLC | 96,927 | $69.8K |
| Susquehanna International Group, LLP | 27,525 | $19.8K |
| UBS Group AG | 4,280 | $3.08K |